A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (NCT05734105)
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.
Who can join: Review the eligibility criteria below.
Location: UC San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (70 Sites)
Showing the first 25 of 70 sites.
- UC San Diego Moores Cancer Center — La Jolla, California
- Yale University — New Haven, Connecticut
- Mayo Clinic Florida — Jacksonville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
- Johns Hopkins Hospital — Baltimore, Maryland
- Boston Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
- Mayo Clinic — Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center — New York, New York
- Northwell Health Cancer Institute/ R.J. Zuckerberg Cancer Center — New York, New York
- Cleveland Clinic — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
- Oregon Health & Science University — Portland, Oregon
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- University of Virginia — Charlottesville, Virginia
- Fred Hutchinson Cancer Center — Seattle, Washington
- Prince of Wales Hospital — Randwick, New South Wales
- Alfred Health — Melbourne, Victoria
- INCA - Instituto Nacional de Cancer — Rio de Janeiro, Rio de Janeiro
- CEPEN - Centro de Pesquisa e Ensino em Saude de Santa Catarina — Florianópolis, Santa Catarina
- Hospital de Cancer de Barretos - Fundacao Pio XII — Barretos, São Paulo
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in GIST
- A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies — Los Angeles, California
- LRG GIST Patient Registry — Wayne, New Jersey
Explore by condition: All GIST clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.